Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report report published on Monday. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $10.00 price target on shares of Arcadia Biosciences in a research note on Friday, April 5th.

Arcadia Biosciences Stock Performance

RKDA opened at $2.05 on Monday. The stock has a market cap of $2.79 million, a price-to-earnings ratio of -0.15 and a beta of 0.60. Arcadia Biosciences has a fifty-two week low of $1.85 and a fifty-two week high of $7.30. The firm’s fifty day moving average is $2.33 and its 200 day moving average is $2.71.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Thursday, March 28th. The basic materials company reported ($2.48) EPS for the quarter, topping the consensus estimate of ($2.68) by $0.20. The business had revenue of $1.17 million for the quarter, compared to analysts’ expectations of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative return on equity of 81.56%. On average, equities research analysts predict that Arcadia Biosciences will post -5.01 earnings per share for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.